Keywords: GlycoMimetics, Pfizer, Rare diseaes, Sickle cell disease, Vaso-occlusive crisis

GlycoMimetics could earn $340 million from Pfizer in rare disease drug licensing deal

Article | 12 October 2011

Print This

Global drugs behemoth Pfizer (NYSE: PFE) has made another foray into the rare disease therapy sector, negotiating an exclusive worldwide ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in